Page 148 - Haematologica Vol. 110 - January 2025

ARTICLE - Immune microenvironment in nodal PTCL
P. Stephan et al.
3. de Leval L, Parrens M, Le Bras F, et al. Angioimmunoblastic T-cell lymphoma is the most common T-cell lymphoma in two distinct French information data sets. Haematologica. 2015;100(9):e361-364.
4. Armand P, Shipp MA, Ribrag V, et al. Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure. J Clin Oncol. 2016;34(31):3733-3739.
5. Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med. 2015;372(4):311-319.
6. Bennani NN, Kim HJ, Pederson LD, et al. Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogression. J Immunother Cancer. 2022;10(6):e004984.
7. Shi Y, Wu J, Wang Z, et al. Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002). J Hematol Oncol. 2021;14(1):12.
8. Ratner L, Waldmann TA, Janakiram M, Brammer JE. Rapid progression of adult T-cell leukemia-lymphoma after PD-1 inhibitor therapy. N Engl J Med. 2018;378(20):1947-1948.
9. Wartewig T, Kurgyis Z, Keppler S, et al. PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis. Nature. 2017;552(7683):121-125.
10. Wilcox RA, Wada DA, Ziesmer SC, et al. Monocytes promote tumor cell survival in T-cell lymphoproliferative disorders and are impaired in their ability to differentiate into mature dendritic cells. Blood. 2009;114(14):2936-2944.
11. Ham JS, Park HY, Ryu KJ, Ko YH, Kim WS, Kim SJ. Elevated serum interleukin-10 level and M2 macrophage infiltration are associated with poor survival in angioimmunoblastic T-cell lymphoma. Oncotarget. 2017;8(44):76231-76240.
12. Sugio T, Miyawaki K, Kato K, et al. Microenvironmental immune cell signatures dictate clinical outcomes for PTCL-NOS. Blood Adv. 2018;2(17):2242-2252.
13. Zhu Q, Deng X, Yao W, et al. Novel tumour-infiltrating lymphocyte-related risk stratification based by flow cytometry for patients with de novo angioimmunoblastic T cell lymphoma. Ann Hematol. 2021;100(3):715-723.
14. Chen Z, Zhu Q, Deng X, et al. Angioimmunoblastic T-cell lymphoma with predominant CD8+ tumor-infiltrating T-cells is a distinct immune pattern with an immunosuppressive microenvironment. Front Immunol. 2022;13:987227.
15. Ohue Y, Nishikawa H. Regulatory T (Treg) cells in cancer: can Treg cells be a new therapeutic target? Cancer Sci. 2019;110(7):2080-2089.
16. Lundberg J, Berglund D, Molin D, Kinch A. Intratumoral expression of FoxP3-positive regulatory T-cells in T-cell lymphoma: no correlation with survival. Ups J Med Sci. 2019;124(2):105-110.
17. Bruneau J, Canioni D, Renand A, et al. Regulatory T-cell depletion in angioimmunoblastic T-cell lymphoma. Am J Pathol. 2010;177(2):570-574.
18. Pritchett JC, Yang ZZ, Kim HJ, et al. High-dimensional and single-cell transcriptome analysis of the tumor microenvironment in angioimmunoblastic T cell lymphoma (AITL). Leukemia. 2022;36(1):165-176.
19. Gaulard P, de Leval L. Follicular helper T cells: implications in neoplastic hematopathology. Semin Diagn Pathol. 2011;28(3):202-213.
20. Judge SJ, Dunai C, Aguilar EG, et al. Minimal PD-1 expression in mouse and human NK cells under diverse conditions. J Clin
Invest. 2020;130(6):3051-3068.
21. Moesta AK, Li XY, Smyth MJ. Targeting CD39 in cancer. Nat Rev
Immunol. 2020;20(12):739-755.
22. Fujisawa M, Nguyen TB, Abe Y, et al. Clonal germinal center B
cells function as a niche for T-cell lymphoma. Blood.
2022;140(18):1937-1950.
23. Delfau-Larue MH, de Leval L, Joly B, et al. Targeting
intratumoral B cells with rituximab in addition to CHOP in angioimmunoblastic T-cell lymphoma. A clinicobiological study of the GELA. Haematologica. 2012;97(10):1594-1602.
24. Querfeld C, Leung S, Myskowski PL, et al. Primary T cells from cutaneous T-cell lymphoma skin explants display an exhausted immune checkpoint profile. Cancer Immunol Res. 2018;6(8):900-909.
25. Heming M, Haessner S, Wolbert J, et al. Intratumor heterogeneity and T cell exhaustion in primary CNS lymphoma. Genome Med. 2022;14(1):109.
26. Yang ZZ, Liang AB, Ansell SM. T-cell-mediated antitumor immunity in B-cell non-Hodgkin lymphoma: activation, suppression and exhaustion. Leuk Lymphoma. 2015;56(9):2498-2504.
27. Ansell SM, Lin Y. Immunotherapy of lymphomas. J Clin Invest. 2020;130(4):1576-1585.
28. Li X, Liu Z, Mi M, et al. Identification of hub genes and key pathways associated with angioimmunoblastic T-cell lymphoma using weighted gene co-expression network analysis. Cancer Manag Res. 2019;11:5209-5220.
29. Yu J, Song Y, Tian W. How to select IgG subclasses in developing anti-tumor therapeutic antibodies. J Hematol Oncol. 2020;13(1):45.
30. Sharma A, Subudhi SK, Blando J, et al. Anti-CTLA-4 immunotherapy does not deplete FOXP3(+) regulatory T cells (Tregs) in human cancers-Response. Clin Cancer Res. 2019;25(11):3469-3470.
31. Quezada SA, Peggs KS. Lost in translation: deciphering the mechanism of action of anti-human CTLA-4. Clin Cancer Res. 2019;25(4):1130-1132.
32. Ha D, Tanaka A, Kibayashi T, et al. Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti- CTLA-4 antibody. Proc Natl Acad Sci U S A. 2019;116(2):609-618.
33. Semmrich M, Marchand JB, Fend L, et al. Vectorized Treg- depleting alphaCTLA-4 elicits antigen cross-presentation and CD8(+) T cell immunity to reject ‘cold’ tumors. J Immunother Cancer. 2022;10(1):e003488.
34. Nicholson SM, Carlesso G, Cheng LI, et al. Effects of ICOS+ T cell depletion via afucosylated monoclonal antibody MEDI-570 on pregnant cynomolgus monkeys and the developing offspring. Reprod Toxicol. 2017;74:116-133.
35. Chavez JC, Foss FM, MD, William BM, et al. A phase I study of anti-ICOS antibody MEDI-570 for relapsed / refractory (R/R) peripheral T-cell lymphoma (PTCL) and angioimmunoblastic T-cell lymphoma (AITL) (NCI-9930). Blood. 2020;136(Suppl 1):5-6.
36. van Hall T, Andre P, Horowitz A, et al. Monalizumab: inhibiting the novel immune checkpoint NKG2A. J Immunother Cancer. 2019;7(1):263.
37. Perrot I, Michaud HA, Giraudon-Paoli M, et al. Blocking antibodies targeting the CD39/CD73 immunosuppressive pathway unleash immune responses in combination cancer therapies. Cell Rep. 2019;27(8):2411-2425.e9.
38. Nagate Y, Ezoe S, Fujita J, et al. Ectonucleotidase CD39 is highly expressed on ATLL cells and is responsible for their immunosuppressive function. Leukemia. 2021;35(1):107-118.
39. Bensussan A, Janela B, Thonnart N, et al. Identification of CD39 as a marker for the circulating malignant T-cell clone of Sezary
Haematologica | 110 January 2025
140